Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed [Yahoo! Finance]
Inventiva S.A. - American Depository Shares (IVA)
Company Research
Source: Yahoo! Finance
Screening of patients is resuming in sites operating under central IRB in the US. Other sites and countries are expected to resume screening and randomization activities progressively over the next weeks. Last Patient First Visit is currently targeted for first half 2024. Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it has lifted the previously disclosed voluntary pause on screening and randomization of its NATiV3 clinical trial and that sites are resuming screening activities. Following the Suspected Unexpected Serious Adverse Reaction (“SUSAR”) in a patient enrolled in the study, Inventiva chose to voluntarily pause screening and randomization of new
Show less
Read more
Impact Snapshot
Event Time:
IVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVA alerts
High impacting Inventiva S.A. - American Depository Shares news events
Weekly update
A roundup of the hottest topics
IVA
News
- Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2024 Featuring 100+ Companies and 110+ Pipeline Drugs Including Lanifibranor (Inventiva Pharma), MSDC-0602K (Cirius Therapeutics), TERN-501 (Terns Pharma) [Yahoo! Finance]Yahoo! Finance
- Inventiva S.A. (NASDAQ: IVA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F [Yahoo! Finance]Yahoo! Finance
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FGlobeNewswire
- Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
IVA
Sec Filings
- 5/3/24 - Form SC
- 4/3/24 - Form 20-F
- 3/27/24 - Form 6-K
- IVA's page on the SEC website